Ioan Cosma, MD
Nephrology · Portland, MENPI 1356540454
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,704 of the $3,844 with a category attached, or 70.3%. Medtronic accounts for 70.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,347 and has fallen 97.9% since, to $49 in 2025. Among nephrology clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $113.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Mozarc Medical US LLC$871
- Argon Medical Devices, Inc.$175
- Travere Therapeutics, Inc.$46
- Nxstage Medical, Inc.$33
Across 15 payments — averaging $1380.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$15K
- Travere Therapeutics, Inc.$6K
What the payments were for
- Travel & lodging$2,70470%
- Food & beverage$1,12729%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 22 | $2,719 |
| Mozarc Medical US LLC | 8 | $871 |
| Argon Medical Devices, Inc. | 1 | $175 |
| Travere Therapeutics, Inc. | 2 | $46 |
| Nxstage Medical, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,630
- Argyle$752
- Ellipsys$325
- Clot Management$175
How this compares
$3,844 in reported general payments places this provider in the 95th percentile of 42 nephrology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 14 | $83,822 |
| JardianceEmpagliflozin | 22 | $26,902 |
| FarxigaDapagliflozin Propanediol | 16 | $10,394 |
| Sevelamer Carbonate | 19 | $2,433 |
| Potassium Citrate ErPotassium Citrate | 11 | $983 |
| Calcitriol | 30 | $255 |
| Metoprolol Succinate | 16 | $248 |
| Lisinopril | 71 | $234 |
| Amlodipine Besylate | 39 | $231 |
| Losartan Potassium | 37 | $228 |
| Furosemide | 26 | $199 |
| Torsemide | 13 | $161 |
| Doxazosin Mesylate | 13 | $141 |
| Chlorthalidone | 20 | $122 |
| Carvedilol | 14 | $101 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Portland
- Abd Assalam QannusPortland$3K
- Robert IsomPortland$2K
- Alan SegalPortland$783
- Sean HebertPortland$689
- Paul ParkerPortland$620
- Prasheen ShahPortland$163
- Patricia CantlinPortland$82
- Robert HaydenPortland$53
- Zain AlshanablehPortland$52
- John VellaPortland$43
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.